UCB S.A. has presented another set of data, arguably the most significant set yet, on bimekizumab which demonstrated that the investigational interleukin-17A and IL-17F inhibitor proved more effective than Novartis AG's blockbuster IL-17A inhibitor Cosentyx in achieving complete skin clearance in psoriasis patients.
The Belgian company has unveiled topline data from the Phase III BE RADIANT head-to-head study showing that bimekizumab was superior to Cosentyx (secukinumab) as measured by a 100% improvement in the Psoriasis Area and Severity Index (PASI 100) at week 16, the primary endpoint